Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.75 |
| ▸ | MAOB | P27338 | 2/20 | 0.75 |
| ▸ | DRD1 | P21728 | 15/20 | 0.65 |
| ▸ | DRD5 | P21918 | 13/20 | 0.65 |
| ▸ | DRD3 | P35462 | 12/20 | 0.56 |
| ▸ | DRD2 | P14416 | 11/20 | 0.56 |
| ▸ | DRD4 | P21917 | 11/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14685816 | 0.93 | MAOA (0.72) | MAOAMAOBDRD1DRD5DRD3 | |
| SCHEMBL7973918 | 0.88 | DRD1 (0.71) | MAOAMAOBDRD1DRD5DRD3 | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL1002256 | 0.86 | DRD1 (0.60) | MAOAMAOBDRD1DRD5DRD3 | |
| SCHEMBL29390912 | 0.86 | MAOA (1.00) | MAOAMAOBDRD1DRD5DRD3 | |
| SCHEMBL98108 | 0.86 | MAOA (1.00) | MAOAMAOBDRD1DRD5DRD3 | |
| Hydrochloric Acid SCHEMBL23501375 | 0.84 | MAOA (1.00) | MAOAMAOBDRD1DRD5DRD3 | |
| SCHEMBL4320673 | 0.82 | MAOA (0.91) | MAOAMAOBDRD1DRD5DRD3 | |
| SCHEMBL130712 | 0.80 | MAOA (0.71) | MAOAMAOBDRD1DRD5DRD3 | |
| SCHEMBL28072797 | 0.78 | MAOA (0.83) | MAOAMAOBDRD1DRD5DRD3 | |
| SCHEMBL18904075 | 0.78 | DRD1 (0.52) | MAOAMAOBDRD1DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023164050-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-4223746-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL | Zeon Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-3483141-B1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL | ZEON CORP (JP) | 2023-07-19 | — | — | EP | disclosed |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns, Inc. | 2023-05-18 | — | — | US | disclosed |
| WO-2023076237-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11345180-B2 | Display medium for assessment and method for manufacturing same | ZEON CORPORATION (JP) | 2022-05-31 | — | — | US | disclosed |
| US-11091452-B2 | Polymerizable compound, polymerizable composition, polymer, optically anisotropic body, and method for producing polymerizable compound | ZEON CORPORATION (JP) | 2021-08-17 | — | — | US | disclosed |
| US-11067731-B2 | Transfer body for optical film, optical film, organic electroluminescent display device, and method for manufacturing optical film | ZEON CORPORATION (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-7456162-B2 | Benzofuran derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-7420070-B2 | Process for preparing optically active 2,3-dihydrobenzofuran compounds | TAKODA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-02 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| EP-1221440-B1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | OTSUKA PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | MAOA 109/4885MAOB 207/4885DRD1 3321/4885 |
| US-11091452-B2 | Polymerizable compound, polymerizable composition, polymer, optically anisotropic body, and method for producing polymerizable compound | PDE8A, MAPT, PLK4 | MAOA 671/4885MAOB 610/4885DRD1 523/4885 |
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | NES, MKI67, CCNO | MAOA 588/4885MAOB 279/4885DRD1 2224/4885 |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | S1PR1, S1PR3, S1PR2 | MAOA 3402/4885MAOB 2689/4885DRD1 875/4885 |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | MAOA 4268/4885MAOB 4347/4885DRD1 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.